We set out to test this hypothesis by analyzing the gene expression signatures of vitamin D supplementation within major immune cell subsets (CD4+ T cells, CD14+ monocytes, and CD19+ B cells) from peripheral blood mononuclear cells (PBMCs) drawn from MS patients enrolled in a six-month trial of high-dose vitamin D supplementation. This evidence concerns the gene CD19 and myeloid sarcoma.